Durvalumab vs Erlotinib

Durvalumab vs Erlotinib: Overview

This comparison examines the pharmacological differences between Durvalumab and Erlotinib.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Erlotinib: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Erlotinib — 36 hours.

Chemical Properties

Molecular Formula: Erlotinib — C22H23N3O4.

Molecular Weight: Erlotinib — 393.4380 g/mol.

Type: Durvalumab — Antibody; Erlotinib — Small molecule.